Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Mark Nicholas Namchuk, Ph.D.

Other Positions

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Patten JJ, Keiser PT, Gysi D, Menichetti G, Mori H, Donahue CJ, Gan X, do Valle I, Geoghegan-Barek K, Anantpadma M, Boytz R, Berrigan JL, Hulsey-Stubbs S, Ayazika T, O'Leary C, Jalloh S, Wagner F, Ayehunie S, Elledge SJ, Anderson D, Loscalzo J, Zitnik M, Gummuluru S, Namchuk MN, Barabási AL, Davey RA. Identification of druggable host targets needed for SARS-CoV-2 infection by combined pharmacological evaluation and cellular network directed prioritization both in vitro and in vivo. bioRxiv. 2022 Feb 01. PMID: 33907750.
  2. Toledo FGS, Martin WF, Morrow L, Beysen C, Bajorunas D, Jiang Y, Silverman BL, McDonnell D, Namchuk MN, Newcomer JW, Graham C. Insulin and glucose metabolism with olanzapine and a combination of olanzapine and samidorphan: exploratory phase 1 results in healthy volunteers. Neuropsychopharmacology. 2022 02; 47(3):696-703. PMID: 34887529.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  3. MacDonald EA, Frey G, Namchuk MN, Harrison SC, Hinshaw SM, Windsor IW. Recognition of Divergent Viral Substrates by the SARS-CoV-2 Main Protease. ACS Infect Dis. 2021 09 10; 7(9):2591-2595. PMID: 34437808.
    Citations: 4     Fields:    Translation:HumansCells
  4. Namchuk MN. Early Returns on Small Molecule Therapeutics for SARS-CoV-2. ACS Infect Dis. 2021 06 11; 7(6):1298-1302. PMID: 33417425.
    Citations: 6     Fields:    Translation:HumansCellsPHPublic Health
  5. Gorgulla C, Padmanabha Das KM, Leigh KE, Cespugli M, Fischer PD, Wang ZF, Tesseyre G, Pandita S, Shnapir A, Calderaio A, Gechev M, Rose A, Lewis N, Hutcheson C, Yaffe E, Luxenburg R, Herce HD, Durmaz V, Halazonetis TD, Fackeldey K, Patten JJ, Chuprina A, Dziuba I, Plekhova A, Moroz Y, Radchenko D, Tarkhanova O, Yavnyuk I, Gruber C, Yust R, Payne D, Näär AM, Namchuk MN, Davey RA, Wagner G, Kinney J, Arthanari H. A multi-pronged approach targeting SARS-CoV-2 proteins using ultra-large virtual screening. iScience. 2021 Feb 19; 24(2):102021. PMID: 33426509.
    Citations: 9     
  6. Gorgulla C, Padmanabha Das KM, Leigh KE, Cespugli M, Fischer PD, Wang ZF, Tesseyre G, Pandita S, Shnapir A, Calderaio A, Gechev M, Rose A, Lewis N, Hutcheson C, Yaffe E, Luxenburg R, Herce HD, Durmaz V, Halazonetis TD, Fackeldey K, Patten JJ, Chuprina A, Dziuba I, Plekhova A, Moroz Y, Radchenko D, Tarkhanova O, Yavnyuk I, Gruber C, Yust R, Payne D, Näär AM, Namchuk MN, Davey RA, Wagner G, Kinney J, Arthanari H. A Multi-Pronged Approach Targeting SARS-CoV-2 Proteins Using Ultra-Large Virtual Screening. ChemRxiv. 2020 Jul 24. PMID: 33200116.
    Citations: 1     
  7. Martin W, Graham C, Morrow L, Beysen C, Toledo FGS, Bajorunas D, Jiang Y, Silverman B, McDonnell D, Namchuk MN, Newcomer JW. 184 Insulin Sensitivity and Glucose Metabolism of Olanzapine and Combination Olanzapine and Samidorphan: A Phase 1 Exploratory Study in Healthy Volunteers. CNS Spectr. 2020 Apr; 25(2):316. PMID: 32331073.
  8. Cunningham JI, Eyerman DJ, Todtenkopf MS, Dean RL, Deaver DR, Sanchez C, Namchuk M. Samidorphan mitigates olanzapine-induced weight gain and metabolic dysfunction in rats and non-human primates. J Psychopharmacol. 2019 10; 33(10):1303-1316. PMID: 31294646.
    Citations: 4     Fields:    Translation:Animals
  9. Gold ER, Ali-Khan SE, Allen L, Ballell L, Barral-Netto M, Carr D, Chalaud D, Chaplin S, Clancy MS, Clarke P, Cook-Deegan R, Dinsmore AP, Doerr M, Federer L, Hill SA, Jacobs N, Jean A, Jefferson OA, Jones C, Kahl LJ, Kariuki TM, Kassel SN, Kiley R, Kittrie ER, Kramer B, Lee WH, MacDonald E, Mangravite LM, Marincola E, Mietchen D, Molloy JC, Namchuk M, Nosek BA, Paquet S, Pirmez C, Seyller A, Skingle M, Spadotto SN, Staniszewska S, Thelwall M. An open toolkit for tracking open science partnership implementation and impact. Gates Open Res. 2019; 3:1442. PMID: 31850398.
    Citations: 4     
  10. Bidlack JM, Knapp BI, Deaver DR, Plotnikava M, Arnelle D, Wonsey AM, Fern Toh M, Pin SS, Namchuk MN. In Vitro Pharmacological Characterization of Buprenorphine, Samidorphan, and Combinations Being Developed as an Adjunctive Treatment of Major Depressive Disorder. J Pharmacol Exp Ther. 2018 11; 367(2):267-281. PMID: 30108159.
    Citations: 12     Fields:    Translation:HumansAnimalsCells
  11. Germann UA, Furey BF, Markland W, Hoover RR, Aronov AM, Roix JJ, Hale M, Boucher DM, Sorrell DA, Martinez-Botella G, Fitzgibbon M, Shapiro P, Wick MJ, Samadani R, Meshaw K, Groover A, DeCrescenzo G, Namchuk M, Emery CM, Saha S, Welsch DJ. Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib). Mol Cancer Ther. 2017 11; 16(11):2351-2363. PMID: 28939558.
    Citations: 44     Fields:    Translation:HumansAnimalsCells
  12. Hickey MB, Merisko-Liversidge E, Remenar JF, Namchuk M. Delivery of long-acting injectable antivirals: best approaches and recent advances. Curr Opin Infect Dis. 2015 Dec; 28(6):603-10. PMID: 26524333.
    Citations: 5     Fields:    Translation:Humans
  13. Farmer LJ, Ledeboer MW, Hoock T, Arnost MJ, Bethiel RS, Bennani YL, Black JJ, Brummel CL, Chakilam A, Dorsch WA, Fan B, Cochran JE, Halas S, Harrington EM, Hogan JK, Howe D, Huang H, Jacobs DH, Laitinen LM, Liao S, Mahajan S, Marone V, Martinez-Botella G, McCarthy P, Messersmith D, Namchuk M, Oh L, Penney MS, Pierce AC, Raybuck SA, Rugg A, Salituro FG, Saxena K, Shannon D, Shlyakter D, Swenson L, Tian SK, Town C, Wang J, Wang T, Wannamaker MW, Winquist RJ, Zuccola HJ. Discovery of VX-509 (Decernotinib): A Potent and Selective Janus Kinase 3 Inhibitor for the Treatment of Autoimmune Diseases. J Med Chem. 2015 Sep 24; 58(18):7195-216. PMID: 26230873.
    Citations: 15     Fields:    Translation:HumansAnimalsCells
  14. Giroux S, Xu J, Reddy TJ, Morris M, Cottrell KM, Cadilhac C, Henderson JA, Nicolas O, Bilimoria D, Denis F, Mani N, Ewing N, Shawgo R, L'Heureux L, Selliah S, Chan L, Chauret N, Berlioz-Seux F, Namchuk MN, Grillot AL, Bennani YL, Das SK, Maxwell JP. Discovery of Thienoimidazole-Based HCV NS5A Genotype 1a and 1b Inhibitors. ACS Med Chem Lett. 2014 Mar 13; 5(3):240-3. PMID: 24900811.
  15. Heidary DK, Huang G, Boucher D, Ma J, Forster C, Grey R, Xu J, Arnost M, Choquette D, Chen G, Zhou JH, Yao YM, Ball ED, Namchuk M, Davies RJ, Henkel G. VX-322: a novel dual receptor tyrosine kinase inhibitor for the treatment of acute myelogenous leukemia. J Med Chem. 2012 Jan 26; 55(2):725-34. PMID: 22221201.
    Citations: 2     Fields:    Translation:HumansAnimalsCells
  16. Davies RJ, Pierce AC, Forster C, Grey R, Xu J, Arnost M, Choquette D, Galullo V, Tian SK, Henkel G, Chen G, Heidary DK, Ma J, Stuver-Moody C, Namchuk M. Design, synthesis, and evaluation of a novel dual FMS-like tyrosine kinase 3/stem cell factor receptor (FLT3/c-KIT) inhibitor for the treatment of acute myelogenous leukemia. J Med Chem. 2011 Oct 27; 54(20):7184-92. PMID: 21970471.
    Citations:    Fields:    Translation:HumansAnimalsCells
  17. Wang T, Duffy JP, Wang J, Halas S, Salituro FG, Pierce AC, Zuccola HJ, Black JR, Hogan JK, Jepson S, Shlyakter D, Mahajan S, Gu Y, Hoock T, Wood M, Furey BF, Frantz JD, Dauffenbach LM, Germann UA, Fan B, Namchuk M, Bennani YL, Ledeboer MW. Janus kinase 2 inhibitors. Synthesis and characterization of a novel polycyclic azaindole. J Med Chem. 2009 Dec 24; 52(24):7938-41. PMID: 20014869.
    Citations: 6     Fields:    Translation:AnimalsCells
  18. Maltais F, Jung YC, Chen M, Tanoury J, Perni RB, Mani N, Laitinen L, Huang H, Liao S, Gao H, Tsao H, Block E, Ma C, Shawgo RS, Town C, Brummel CL, Howe D, Pazhanisamy S, Raybuck S, Namchuk M, Bennani YL. In vitro and in vivo isotope effects with hepatitis C protease inhibitors: enhanced plasma exposure of deuterated telaprevir versus telaprevir in rats. J Med Chem. 2009 Dec 24; 52(24):7993-8001. PMID: 19894743.
    Citations: 6     Fields:    Translation:HumansAnimalsCells
  19. Aronov AM, Tang Q, Martinez-Botella G, Bemis GW, Cao J, Chen G, Ewing NP, Ford PJ, Germann UA, Green J, Hale MR, Jacobs M, Janetka JW, Maltais F, Markland W, Namchuk MN, Nanthakumar S, Poondru S, Straub J, ter Haar E, Xie X. Structure-guided design of potent and selective pyrimidylpyrrole inhibitors of extracellular signal-regulated kinase (ERK) using conformational control. J Med Chem. 2009 Oct 22; 52(20):6362-8. PMID: 19827834.
    Citations: 49     Fields:    Translation:Cells
  20. Aronov AM, Baker C, Bemis GW, Cao J, Chen G, Ford PJ, Germann UA, Green J, Hale MR, Jacobs M, Janetka JW, Maltais F, Martinez-Botella G, Namchuk MN, Straub J, Tang Q, Xie X. Flipped out: structure-guided design of selective pyrazolylpyrrole ERK inhibitors. J Med Chem. 2007 Mar 22; 50(6):1280-7. PMID: 17300186.
    Citations: 32     Fields:    Translation:Cells
  21. Wannamaker W, Davies R, Namchuk M, Pollard J, Ford P, Ku G, Decker C, Charifson P, Weber P, Germann UA, Kuida K, Randle JC. (S)-1-((S)-2-{[1-(4-amino-3-chloro-phenyl)-methanoyl]-amino}-3,3-dimethyl-butanoyl)-pyrrolidine-2-carboxylic acid ((2R,3S)-2-ethoxy-5-oxo-tetrahydro-furan-3-yl)-amide (VX-765), an orally available selective interleukin (IL)-converting enzyme/caspase-1 inhibitor, exhibits potent anti-inflammatory activities by inhibiting the release of IL-1beta and IL-18. J Pharmacol Exp Ther. 2007 May; 321(2):509-16. PMID: 17289835.
    Citations: 93     Fields:    Translation:HumansAnimals
  22. Shao Z, Bhattacharya K, Hsich E, Park L, Walters B, Germann U, Wang YM, Kyriakis J, Mohanlal R, Kuida K, Namchuk M, Salituro F, Yao YM, Hou WM, Chen X, Aronovitz M, Tsichlis PN, Bhattacharya S, Force T, Kilter H. c-Jun N-terminal kinases mediate reactivation of Akt and cardiomyocyte survival after hypoxic injury in vitro and in vivo. Circ Res. 2006 Jan 06; 98(1):111-8. PMID: 16306447.
    Citations: 58     Fields:    Translation:HumansAnimalsCells
  23. Force T, Kuida K, Namchuk M, Parang K, Kyriakis JM. Inhibitors of protein kinase signaling pathways: emerging therapies for cardiovascular disease. Circulation. 2004 Mar 16; 109(10):1196-205. PMID: 15023894.
    Citations: 36     Fields:    Translation:HumansAnimalsCells
  24. Walters WP, Namchuk M. Designing screens: how to make your hits a hit. Nat Rev Drug Discov. 2003 Apr; 2(4):259-66. PMID: 12669025.
    Citations: 90     Fields:    Translation:Humans
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Namchuk's Networks
Click the
buttons for more information and interactive visualizations!
Concepts (139)
Co-Authors (10)
Similar People (60)
Same Department 
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.